Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALLO-715 + nirogacestat
- Development stage
- Unknown
- Lead developer
- Allogene Therapeutics
- Modality
- Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Oral
01
Overview
ALLO-715 + nirogacestat is an investigational combination therapy consisting of ALLO-715, an allogeneic anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy, and nirogacestat, a small-molecule gamma-secretase inhibitor. ALLO-715 is engineered using TALEN gene-editing to delete TRAC and CD52 genes, reducing risk of graft-versus-host disease and enhancing lymphodepletion. Nirogacestat increases cell-surface BCMA expression, potentially enhancing anti-myeloma efficacy of BCMA-targeting therapies. The combination is being studied for relapsed/refractory multiple myeloma. ALLO-715 is developed by Allogene Therapeutics; nirogacestat is developed and manufactured by SpringWorks Therapeutics[1][2][4][5][6].
- Other names
- ALLO-715ALLO715ALLO 715Ogsiveo
02
Targets
GSEC (Gamma-Secretase Complex)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on ALLO-715 + nirogacestat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALLO-715 + nirogacestat.